Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
A Phase I Trial of CD19-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12) and With a Truncated Human Epidermal Growth Factor Receptor (EGFRt) in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
Sponsor: Roswell Park Cancer Institute
Terminated
Manufacturing issues
Other terminated trials from Roswell Park Cancer Institute
Other Recurrent Chronic Lymphocytic Leukemia trials with similar outcome
Listed as NCT06343376, this PHASE1 trial focuses on Recurrent Chronic Lymphocytic Leukemia and Recurrent Diffuse Large B-Cell Lymphoma and remains terminated or withdrawn. Sponsored by Roswell Park Cancer Institute, it has been updated 9 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Apr 2025 — Sep 2025 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jan 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Roswell Park Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .